Trethera

Coming – August 12

One Drug. Multiple Billion-Dollar Shots On Goal.

Date and Time

August 12

–

1:00 PM ET / 10:00 AM PT

Details will be provided upon RSVP approval

About this Event

Most biotechnology companies are built around a single disease. Trethera is built around an untapped biological pathway that offers multiple shots on goal.

Trethera’s drug, TRE-515, is a first-in-class oral therapy targets dCK, an enzyme in the DNA salvage pathway that is highly active across many solid tumors, autoimmune diseases, and inflammatory disorders. Rather than pursuing a portfolio of products, Trethera is advancing one mechanism that has the potential to work across multiple indications.

TRE-515 completed Phase 1 dose escalation in over 30 patients with advanced solid tumors and subsequently received FDA Fast Track designation for metastatic prostate cancer. Encouraging observations from an FDA-authorized Expanded Access patient supported initiation of an ALS trial (n=6) at Massachusetts General Hospital. TRE-515 has also received an Orphan Drug designation for optic neuritis, inflammation of the optic nerve which typically causes vision loss and pain with eye movement.

Join our executive briefing with Trethera Chairman & CEO, Kenneth A. Schultz, MD, who will share how their “pipeline-in-a-product” strategy allows each successful indication to increase the value of the same core asset without requiring development of an entirely new drug.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.